RKDA Quote, Financials, Valuation and Earnings

Bridgford Foods Corp. has a net margin of 65.75% compared to Arcadia Biosciences, Inc.'s net margin of -3.15%. Arcadia Biosciences, Inc.'s return on equity of -71.48% beat Bridgford Foods Corp.'s return on equity of -5.79%.

Arcadia Biosciences, Inc. has a consensus price target of $12.00, signalling upside risk potential of 273.83%. On the other hand Bridgford Foods Corp. has an analysts' consensus of -- which suggests that it could fall by --. Given that Arcadia Biosciences, Inc. has higher upside potential than Bridgford Foods Corp., analysts believe Arcadia Biosciences, Inc. is more attractive than Bridgford Foods Corp..

Arcadia Biosciences, Inc. has a beta of 0.476, which suggesting that the stock is 52.388% less volatile than S&P 500. In comparison Bridgford Foods Corp. has a beta of -0.249, suggesting its less volatile than the S&P 500 by 124.925%.

Arcadia Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bridgford Foods Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcadia Biosciences, Inc. pays -- of its earnings as a dividend. Bridgford Foods Corp. pays out -- of its earnings as a dividend.

Arcadia Biosciences, Inc. quarterly revenues are $1.3M, which are smaller than Bridgford Foods Corp. quarterly revenues of $52M. Arcadia Biosciences, Inc.'s net income of $856K is higher than Bridgford Foods Corp.'s net income of -$1.6M. Notably, Arcadia Biosciences, Inc.'s price-to-earnings ratio is -- while Bridgford Foods Corp.'s PE ratio is 62.73x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcadia Biosciences, Inc. is 0.85x versus 0.29x for Bridgford Foods Corp.. Usually stocks with elevated PS ratios are considered overvalued.

The Hain Celestial Group, Inc. has a net margin of 65.75% compared to Arcadia Biosciences, Inc.'s net margin of -5.61%. Arcadia Biosciences, Inc.'s return on equity of -71.48% beat The Hain Celestial Group, Inc.'s return on equity of -78.55%.

Arcadia Biosciences, Inc. has a consensus price target of $12.00, signalling upside risk potential of 273.83%. On the other hand The Hain Celestial Group, Inc. has an analysts' consensus of $2.41 which suggests that it could grow by 111.73%. Given that Arcadia Biosciences, Inc. has higher upside potential than The Hain Celestial Group, Inc., analysts believe Arcadia Biosciences, Inc. is more attractive than The Hain Celestial Group, Inc..

Arcadia Biosciences, Inc. has a beta of 0.476, which suggesting that the stock is 52.388% less volatile than S&P 500. In comparison The Hain Celestial Group, Inc. has a beta of 0.607, suggesting its less volatile than the S&P 500 by 39.35%.

Arcadia Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. The Hain Celestial Group, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcadia Biosciences, Inc. pays -- of its earnings as a dividend. The Hain Celestial Group, Inc. pays out -- of its earnings as a dividend.

Arcadia Biosciences, Inc. quarterly revenues are $1.3M, which are smaller than The Hain Celestial Group, Inc. quarterly revenues of $367.9M. Arcadia Biosciences, Inc.'s net income of $856K is higher than The Hain Celestial Group, Inc.'s net income of -$20.6M. Notably, Arcadia Biosciences, Inc.'s price-to-earnings ratio is -- while The Hain Celestial Group, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcadia Biosciences, Inc. is 0.85x versus 0.07x for The Hain Celestial Group, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Healthy Choice Wellness Corp. has a net margin of 65.75% compared to Arcadia Biosciences, Inc.'s net margin of -3.52%. Arcadia Biosciences, Inc.'s return on equity of -71.48% beat Healthy Choice Wellness Corp.'s return on equity of -43.51%.

Arcadia Biosciences, Inc. has a consensus price target of $12.00, signalling upside risk potential of 273.83%. On the other hand Healthy Choice Wellness Corp. has an analysts' consensus of $2.00 which suggests that it could grow by 604.23%. Given that Healthy Choice Wellness Corp. has higher upside potential than Arcadia Biosciences, Inc., analysts believe Healthy Choice Wellness Corp. is more attractive than Arcadia Biosciences, Inc..

Arcadia Biosciences, Inc. has a beta of 0.476, which suggesting that the stock is 52.388% less volatile than S&P 500. In comparison Healthy Choice Wellness Corp. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Arcadia Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Healthy Choice Wellness Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcadia Biosciences, Inc. pays -- of its earnings as a dividend. Healthy Choice Wellness Corp. pays out -- of its earnings as a dividend.

Arcadia Biosciences, Inc. quarterly revenues are $1.3M, which are smaller than Healthy Choice Wellness Corp. quarterly revenues of $20.3M. Arcadia Biosciences, Inc.'s net income of $856K is higher than Healthy Choice Wellness Corp.'s net income of -$712.4K. Notably, Arcadia Biosciences, Inc.'s price-to-earnings ratio is -- while Healthy Choice Wellness Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcadia Biosciences, Inc. is 0.85x versus 0.05x for Healthy Choice Wellness Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Laird Superfood, Inc. has a net margin of 65.75% compared to Arcadia Biosciences, Inc.'s net margin of -7.56%. Arcadia Biosciences, Inc.'s return on equity of -71.48% beat Laird Superfood, Inc.'s return on equity of -14.38%.

Arcadia Biosciences, Inc. has a consensus price target of $12.00, signalling upside risk potential of 273.83%. On the other hand Laird Superfood, Inc. has an analysts' consensus of $7.67 which suggests that it could grow by 254.94%. Given that Arcadia Biosciences, Inc. has higher upside potential than Laird Superfood, Inc., analysts believe Arcadia Biosciences, Inc. is more attractive than Laird Superfood, Inc..

Arcadia Biosciences, Inc. has a beta of 0.476, which suggesting that the stock is 52.388% less volatile than S&P 500. In comparison Laird Superfood, Inc. has a beta of 2.351, suggesting its more volatile than the S&P 500 by 135.079%.

Arcadia Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Laird Superfood, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcadia Biosciences, Inc. pays -- of its earnings as a dividend. Laird Superfood, Inc. pays out -- of its earnings as a dividend.

Arcadia Biosciences, Inc. quarterly revenues are $1.3M, which are smaller than Laird Superfood, Inc. quarterly revenues of $12.9M. Arcadia Biosciences, Inc.'s net income of $856K is higher than Laird Superfood, Inc.'s net income of -$975.1K. Notably, Arcadia Biosciences, Inc.'s price-to-earnings ratio is -- while Laird Superfood, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcadia Biosciences, Inc. is 0.85x versus 0.47x for Laird Superfood, Inc.. Usually stocks with elevated PS ratios are considered overvalued.